Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT05734391 |
Other study ID # |
851492 |
Secondary ID |
|
Status |
Completed |
Phase |
|
First received |
|
Last updated |
|
Start date |
October 1, 2022 |
Est. completion date |
December 20, 2023 |
Study information
Verified date |
March 2024 |
Source |
University of Pennsylvania |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Observational
|
Clinical Trial Summary
The aims of this project, called "Surveillance of Healthcare-associated infections &
Antimicrobial Resistance", or "SHARE", are to 1) enhance laboratory capacity to detect
emerging AMR patterns; 2) strengthen hospital epidemiology programs to use data to prevent,
detect, and contain emerging AMR threats; 3) deploy study teams to answer critical public
health surveillance questions, and 4) to build a national network of infection prevention and
control (IPC) resources to prevent, detect, and contain emerging infectious disease threats
Description:
The World Health Organization (WHO) has declared antimicrobial resistance (AMR) one of the
top 10 global public health threats facing humanity. AMR burden is higher in
low-and-middle-income countries (LMICs) where, in recent decades, incidence and mortality
from healthcare-associated infections (HAI) due to multidrug resistant organisms (MDRO) have
dramatically increased. For example, neonatal sepsis is the third most common cause of
neonatal deaths and multidrug-resistant Gram-negative bacteria are now the leading cause of
sepsis among hospitalized neonates in south Asia and sub-Saharan Africa, including
Botswana.1,2 One in three newborns with an MDRO bloodstream infection will die.3 In 2021, to
respond to the global threat of AMR, U.S. Centers for Disease Control & Prevention (CDC)
announced the launch of a global "network of networks" to tackle the problem of AMR and
healthcare-associated infections (HAIs). The network, called "Global Antimicrobial Resistance
Laboratory and Response Network", solicited funding applications; in December of 2021,
Botswana was announced as recipient of a 5-year cooperative agreement following the
successful application for funding for a comprehensive AMR surveillance project. The project
was developed by investigators from Botswana-UPenn Partnership (BUP) in collaboration with
Botswana's Ministry of Health & Wellness (MOHW) and the University of Botswana (UB).